EARLY DOSE OPTIMIZATION IN NONRESPONDERS TO GOLIMUMAB INDUCTION TREATMENT FOR ULCERATIVE COLITIS IS SUPPORTED BY PHARMACOKINETIC DATA THROUGH 1 YEAR

George Philip  1     Colleen W. Marano  2     Omoniyi J. Adedokun  3     Richard Melsheimer  4     Freddy Cornillie  5    
1 Merck & Co., Inc.,Upper Gwynedd,United States
2 Janssen Pharmaceutical Immunology - GI,Spring House,United States
3 Janssen R&D, LLC.,Spring House,United States
4 Janssen Biologics Medical Affairs,Leiden,Netherlands
5 Merck & Co., Inc.,Kenilworth,United States

Conference
UEG Week 2018

Citation
United European Gastroenterology Journal 2018; 6 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at office@ueg.eu

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing